Product image of Methotrexate Viatris (Methotrexate) supplied by GNH India

Methotrexate Viatris

Active Ingredient:
Methotrexate
Origin:
EU

Methotrexate Viatris (Methotrexate)

Methotrexate, the active ingredient in Methotrexate Viatris, is a antimetabolite (folate antagonist) presented as an intravenous solution for intravenous use. It is employed in the management of rheumatoid arthritis, severe psoriasis, acute lymphoblastic leukemia, non‑Hodgkin lymphoma, breast cancer, and ectopic pregnancy under specialist supervision.

GNH India supplies Methotrexate Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, and distributes through regulated channels to ensure quality‑assured product availability for clinical use in compliance with local regulations.

Manufacturer / TM Owner

Viatris Sante

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Methotrexate is an antimetabolite used to modify immune response and inhibit malignant cell proliferation.

  • Rheumatoid arthritis: reduces joint inflammation and slows disease progression.
  • Psoriasis: decreases skin cell proliferation and improves plaque lesions.
  • Acute lymphoblastic leukemia: interferes with leukemic cell replication to achieve remission.
  • Non‑Hodgkin lymphoma: suppresses lymphoma growth as part of combination chemotherapy.
  • Breast cancer: used in high‑dose regimens to enhance cytotoxic effect.
  • Ectopic pregnancy: terminates trophoblastic tissue when surgery is not preferred.

How It Works

  • Methotrexate inhibits the enzyme dihydrofolate reductase, preventing the conversion of dihydrofolate to tetrahydrofolate. This blockade reduces the availability of tetrahydrofolate, a cofactor required for synthesis of purine nucleotides and thymidylate, thereby impairing DNA, RNA and protein synthesis in rapidly dividing cells and modulating immune cell activity.

Side Effects

Adverse reactions may vary in frequency and severity.

Common Side Effects

  • Nausea and vomiting: gastrointestinal upset occurring early in therapy.
  • Fatigue: persistent tiredness reported by many patients.
  • Oral mucositis: painful mouth sores or ulceration.
  • Cytopenias: reduced white blood cells, red blood cells or platelets.
  • Elevated liver enzymes: mild transaminase rise.

Serious or Rare Side Effects

  • Severe hepatotoxicity: potential for liver fibrosis or cirrhosis.
  • Pulmonary toxicity: interstitial pneumonitis or fibrosis.
  • Life‑threatening infection: due to profound immunosuppression.
  • Bone marrow failure: aplastic anemia or pancytopenia.
  • Renal impairment: acute kidney injury from precipitation of drug crystals.

Precautions & Warnings

Careful monitoring and patient education are essential when using methotrexate.

  • Liver monitoring: perform baseline and periodic liver function tests.
  • Hematologic monitoring: check complete blood counts regularly.
  • Pregnancy avoidance: contraindicated in pregnancy; use effective contraception.
  • Folic acid supplementation: administer folic or folinic acid to reduce toxicity.
  • Renal dose adjustment: modify dose in patients with impaired renal function.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Methotrexate has several drug interactions that may require avoidance or close monitoring.

Major Interactions (Avoid)

  • NSAIDs (e.g., ibuprofen, naproxen): increase methotrexate toxicity by reducing renal clearance.
  • Penicillins (e.g., ampicillin): may elevate methotrexate plasma levels.
  • Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

  • Azathioprine: additive bone‑marrow suppression.
  • Warfarin: potentiates anticoagulant effect, requiring INR monitoring.
  • Oral contraceptives: may reduce methotrexate efficacy, consider alternative contraception.

Frequently Asked Questions

Methotrexate Viatris is indicated for rheumatoid arthritis, severe psoriasis, acute lymphoblastic leukemia, non‑Hodgkin lymphoma, breast cancer, and ectopic pregnancy, where it helps control disease activity or eradicate malignant cells under specialist supervision.

Methotrexate blocks dihydrofolate reductase, halting the production of tetrahydrofolate needed for DNA, RNA and protein synthesis. This action suppresses rapidly dividing cells, including immune cells and cancer cells, thereby reducing inflammation and tumor growth.

The prescribed dose of Methotrexate Viatris is determined by the treating physician based on the specific indication, patient weight, renal function and treatment protocol. Only a qualified prescriber can set the appropriate regimen.

Methotrexate is classified as pregnancy category X and is contraindicated in pregnancy because it can cause fetal harm. It is also not recommended while breastfeeding, as it may be excreted in milk and affect the infant.

To request Methotrexate Viatris, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with other immunosuppressants such as azathioprine or biologic agents, methotrexate offers a well‑established oral or intravenous option with a broad range of indications. It has a distinct mechanism targeting folate metabolism, which can be advantageous in certain cancers but may require more intensive monitoring for hepatic and hematologic toxicity.

Methotrexate Viatris should be stored at 2‑8 °C, kept refrigerated, protected from light, and never frozen or shaken. Maintain the original packaging to preserve stability and ensure proper handling during transport.

Methotrexate Viatris is supplied as an intravenous solution and is administered by a qualified healthcare professional via slow IV infusion, following the dosing schedule prescribed by the treating clinician.

The most serious risks include severe liver toxicity, pulmonary fibrosis, life‑threatening infections due to immunosuppression, bone‑marrow failure, and acute renal impairment. Patients should be monitored closely for signs of these complications.

Methotrexate Viatris should not be used by pregnant women, individuals with severe liver disease, uncontrolled infections, significant renal impairment, or those with known hypersensitivity to methotrexate or any component of the formulation.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Methotrexate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT